Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00270-024-03821-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Using Machine Learning to Predict Advanced-Stage Progression of Intermediate-Stage Hepatocellular Carcinoma after Transarterial Chemoembolization.
Radiol Imaging Cancer
September 2025
Department of Radiation Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Road, Guangzhou, China 510080.
Purpose To develop and test a machine learning (ML)-based model that integrates preoperative variables for prediction of advanced-stage progression (ASP) after transarterial chemoembolization (TACE). Materials and Methods This multicenter retrospective study (ResearchRegistry.com identifier no.
View Article and Find Full Text PDFImmune checkpoint blockade and transarterial chemoembolization in liver-limited hepatocellular carcinoma: new questions at the dawn of a new era.
J Immunother Cancer
August 2025
Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Anti-programed cell death protein-1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies combined with anti-vascular endothelial growth factor (VEGF) or anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies are now standard therapeutic options for patients with treatment-naïve, advanced stage, hepatocellular carcinoma. Given the observed efficacy in the advanced setting, the unmet need for therapies for intermediate stage liver cancer, and compelling preclinical rationale for combination with liver-directed therapies, such as transarterial chemoembolization, immunotherapies have quickly moved into earlier stages of the disease. Several phase 1/2 clinical trials have collectively verified the safety of immune checkpoint blockade with regional therapy for intermediate stage, liver-limited, hepatocellular carcinoma.
View Article and Find Full Text PDFCommentary: Case Report: Congenital hepatic hemangioma with arteriovenous fistula: 2-year multidisciplinary management and outcomes.
Front Pediatr
July 2025
Department of Pediatric Surgery & Vascular Anomalies, Xi'an International Medical Center Hospital, Xi'an, China.
Efficacy and challenges of combining transarterial chemoembolization with pembrolizumab in advanced hepatocellular carcinoma: insights from the PETAL study.
Hepatobiliary Surg Nutr
April 2025
Division of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China.
Commentary on "Hepatocellular Carcinoma with Vascular Invasion Treated with Resin Yttrium-90 Transarterial Radioembolization Using Single Compartment Dosimetry".
Cardiovasc Intervent Radiol
April 2025
Department of Radiology, The University of Alabama at Birmingham, Birmingham, USA.